Equities Analysts Issue Forecasts for Cybin Q3 Earnings

Cybin Inc. (NYSE:CYBN) – Equities researchers at HC Wainwright dropped their Q3 2025 earnings per share (EPS) estimates for shares of Cybin in a research report issued to clients and investors on Tuesday, November 19th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.53) for the quarter, down from their prior forecast of ($0.38). HC Wainwright currently has a “Buy” rating and a $190.00 target price on the stock. The consensus estimate for Cybin’s current full-year earnings is ($3.37) per share. HC Wainwright also issued estimates for Cybin’s Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($3.63) EPS, Q1 2026 earnings at ($0.57) EPS, Q2 2026 earnings at ($0.63) EPS, Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.79) EPS, FY2026 earnings at ($2.69) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at $4.22 EPS and FY2029 earnings at $9.57 EPS.

A number of other research firms also recently weighed in on CYBN. Canaccord Genuity Group cut their price target on Cybin from $96.00 to $86.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Cybin in a research note on Wednesday, July 31st.

Cybin Price Performance

CYBN opened at $10.13 on Thursday. Cybin has a fifty-two week low of $6.50 and a fifty-two week high of $21.66. The business’s 50-day moving average price is $9.56. The stock has a market cap of $202.52 million, a P/E ratio of -1.52 and a beta of 0.38.

Institutional Trading of Cybin

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. PEAK6 Investments LLC acquired a new stake in shares of Cybin during the 1st quarter worth approximately $95,000. Sanctuary Advisors LLC acquired a new stake in shares of Cybin during the 2nd quarter worth approximately $36,000. AdvisorShares Investments LLC boosted its stake in Cybin by 13.4% in the 2nd quarter. AdvisorShares Investments LLC now owns 1,865,217 shares of the company’s stock valued at $494,000 after buying an additional 220,403 shares in the last quarter. Ikarian Capital LLC acquired a new stake in Cybin in the 1st quarter valued at $5,770,000. Finally, Rosalind Advisors Inc. boosted its stake in Cybin by 38.3% in the 2nd quarter. Rosalind Advisors Inc. now owns 19,300,000 shares of the company’s stock valued at $5,230,000 after buying an additional 5,340,000 shares in the last quarter. Institutional investors and hedge funds own 17.94% of the company’s stock.

Cybin Company Profile

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.